We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Bladder Cancer

Journal Scan / Research · May 19, 2021

Durvalumab + Targeted Therapies in Advanced Urothelial Cancer

Nature Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

Nature Medicine
An Adaptive, Biomarker-Directed Platform Study of Durvalumab in Combination With Targeted Therapies in Advanced Urothelial Cancer
Nat. Med. 2021 May 01;27(5)793-801, T Powles, D Carroll, S Chowdhury, G Gravis, F Joly, J Carles, A Fléchon, P Maroto, D Petrylak, F Rolland, N Cook, AV Balar, SS Sridhar, MD Galsky, P Grivas, A Ravaud, R Jones, J Cosaert, D Hodgson, I Kozarewa, R Mather, R McEwen, F Mercier, D Landers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading